Xention, founded in 2002 and based in Cambridge, is a biopharmaceutical company specializing in the discovery and development of ion channel modulating drugs. The company focuses on creating treatments for conditions such as atrial fibrillation, overactive bladder, and chronic cough. Xention has initiated the development of multiple drugs and sponsored various clinical trials, ranging from phase 1 to multi-country phase 2b. The company has engaged in numerous research collaborations with international pharmaceutical businesses and has received funding from prestigious organizations like the EU, the Wellcome Trust, and Innovate UK. Notably, Xention developed TA 8995 for dyslipidaemia on behalf of Dezima Pharma BV, which led to Dezima's acquisition by Amgen in 2015 in a deal valued up to $1.55 billion. In 2013, Xention entered a cardiovascular collaboration with Servier to develop a selective Kv1.5 modulator for treating atrial fibrillation.

Keywords: ion channel modulating drugs, atrial fibrillation, overactive bladder, chronic cough, clinical trials, research collaborations, EU funding, Wellcome Trust, Innovate UK, cardiovascular collaboration.